Fennec Pharmaceuticals, Inc. (FENC)
11.74
+0.34
(+2.98%)
USD |
NASDAQ |
Aug 25, 16:00
11.74
0.00 (0.00%)
After-Hours: 19:59
Fennec Pharmaceuticals Net Income (Quarterly) : 1.973M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.973M |
| March 31, 2026 | 0.201M |
| December 31, 2025 | -5.144M |
| September 30, 2025 | -0.638M |
| June 30, 2025 | -3.152M |
| March 31, 2025 | -1.165M |
| December 31, 2024 | -1.619M |
| September 30, 2024 | -5.735M |
| June 30, 2024 | -5.553M |
| March 31, 2024 | 12.84M |
| December 31, 2023 | -2.682M |
| September 30, 2023 | -1.867M |
| June 30, 2023 | -5.444M |
| March 31, 2023 | -6.052M |
| December 31, 2022 | -6.857M |
| September 30, 2022 | -8.089M |
| June 30, 2022 | -5.072M |
| March 31, 2022 | -3.696M |
| December 31, 2021 | -4.427M |
| September 30, 2021 | -4.185M |
| June 30, 2021 | -4.001M |
| March 31, 2021 | -4.733M |
| December 31, 2020 | -3.238M |
| September 30, 2020 | -6.20M |
| June 30, 2020 | -4.845M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.826M |
| December 31, 2019 | -3.61M |
| September 30, 2019 | -1.809M |
| June 30, 2019 | -4.73M |
| March 31, 2019 | -2.626M |
| December 31, 2018 | -2.984M |
| September 30, 2018 | -2.749M |
| June 30, 2018 | -2.587M |
| March 31, 2018 | -1.568M |
| December 31, 2017 | -2.29M |
| September 30, 2017 | -2.352M |
| June 30, 2017 | -1.598M |
| March 31, 2017 | -0.806M |
| December 31, 2016 | -1.143M |
| September 30, 2016 | -0.502M |
| June 30, 2016 | -0.724M |
| March 31, 2016 | -0.42M |
| December 31, 2015 | -0.54M |
| September 30, 2015 | -0.123M |
| June 30, 2015 | -0.173M |
| March 31, 2015 | 0.177M |
| December 31, 2014 | 1.388M |
| September 30, 2014 | 0.38M |
| June 30, 2014 | -0.75M |
| March 31, 2014 | -3.194M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Abeona Therapeutics, Inc. | -20.19M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 17.87M |
| Total Expenses (Quarterly) | 15.90M |
| EPS Diluted (Quarterly) | 0.0542 |
| Enterprise Value | 358.14M |
| Gross Profit Margin (Quarterly) | 95.97% |
| Profit Margin (Quarterly) | 11.04% |
| Earnings Yield | -1.09% |
| Normalized Earnings Yield | -0.7044 |